Search Results
Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Institute for Liver and Digestive Disease, Royal Free Hospital, University College London, London, UK
Search for other papers by Luohai Chen in
Google Scholar
PubMed
Search for other papers by Gopinath Gnanasegaran in
Google Scholar
PubMed
Search for other papers by Dalvinder Mandair in
Google Scholar
PubMed
Search for other papers by Christos Toumpanakis in
Google Scholar
PubMed
Search for other papers by Martyn Caplin in
Google Scholar
PubMed
Search for other papers by Shaunak Navalkissoor in
Google Scholar
PubMed
Introduction 177 Lutetium-DOTA 0 -Tyr 3 -octreotate ( 177 Lu-Dotatate) is a peptide receptor radionuclide therapy (PRRT) licensed for treatment in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours (NET
Search for other papers by Chiara Borga in
Google Scholar
PubMed
Search for other papers by Carlo Alberto Dal Pozzo in
Google Scholar
PubMed
Search for other papers by Elisabetta Trevellin in
Google Scholar
PubMed
Search for other papers by Francesca Bergamo in
Google Scholar
PubMed
Search for other papers by Sabina Murgioni in
Google Scholar
PubMed
Search for other papers by Anna Caterina Milanetto in
Google Scholar
PubMed
Search for other papers by Claudio Pasquali in
Google Scholar
PubMed
Search for other papers by Umberto Cillo in
Google Scholar
PubMed
Search for other papers by Giada Munari in
Google Scholar
PubMed
Search for other papers by Chiara Martini in
Google Scholar
PubMed
Search for other papers by Eugenio De Carlo in
Google Scholar
PubMed
Search for other papers by Vittorina Zagonel in
Google Scholar
PubMed
Search for other papers by Vincenza Guzzardo in
Google Scholar
PubMed
Search for other papers by Gianmaria Pennelli in
Google Scholar
PubMed
Search for other papers by Angelo Paolo Dei Tos in
Google Scholar
PubMed
Search for other papers by Roberto Vettor in
Google Scholar
PubMed
Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
Search for other papers by Matteo Fassan in
Google Scholar
PubMed
-tumoral heterogeneity), where both inter-lesional (between primary tumor and metastatic locations) and intra-lesional (among cells derived from the same clone within the same lesions) heterogeneities are involved. In well-differentiated gastroenteropancreatic NENs
Search for other papers by Benjamin Easton White in
Google Scholar
PubMed
Search for other papers by Maralyn R Druce in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Rajaventhan Srirajaskanthan in
Google Scholar
PubMed
Search for other papers by Eva Maria Gamper in
Google Scholar
PubMed
Search for other papers by Debra Gray in
Google Scholar
PubMed
Search for other papers by Ruben Mujica-Mota in
Google Scholar
PubMed
King’s Health Partners ENETS Centre of Excellence, Kings College hospital, London, UK
Search for other papers by John K Ramage in
Google Scholar
PubMed
) using factor analysis, which has indicated many similarities. The Norfolk QOL-NET questionnaire captured more aspects of flushing, respiratory, and cardiovascular impact. There is limited data on outcomes of therapies in gastroenteropancreatic NETs (GEP
University College London Cancer Institute, Neuroendocrine Tumour Unit, Paul O'Gorman Building, Huntley Street, London WC1E 6BT, UK
Search for other papers by Anna Karpathakis in
Google Scholar
PubMed
Search for other papers by Martyn Caplin in
Google Scholar
PubMed
University College London Cancer Institute, Neuroendocrine Tumour Unit, Paul O'Gorman Building, Huntley Street, London WC1E 6BT, UK
Search for other papers by Christina Thirlwell in
Google Scholar
PubMed
for gastroenteropancreatic (GEP) NETs is shown in Fig. 2 . Figure 2 Flow diagram of therapies for localised and advanced gastroenteropancreatic neuroendocrine tumours. There have been four RCTs of chemotherapy, two in pNETs and two in gastrointestinal
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Francesco Barretta in
Google Scholar
PubMed
Search for other papers by Annalisa Trama in
Google Scholar
PubMed
Search for other papers by Laura Botta in
Google Scholar
PubMed
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Roberto Buzzoni in
Google Scholar
PubMed
University of Milan, Milan, Italy
Search for other papers by Filippo De Braud in
Google Scholar
PubMed
Liver Surgery, Transplantation and Gastroenterology, University of Milan and Istituto Nazionale Tumori Fondazione IRCCS, ENETS Center of Excellence, Milano, Milan, Italy
Search for other papers by Vincenzo Mazzaferro in
Google Scholar
PubMed
Search for other papers by Ugo Pastorino in
Google Scholar
PubMed
Search for other papers by Ettore Seregni in
Google Scholar
PubMed
Search for other papers by Luigi Mariani in
Google Scholar
PubMed
Search for other papers by Gemma Gatta in
Google Scholar
PubMed
Search for other papers by Maria Di Bartolomeo in
Google Scholar
PubMed
Search for other papers by Daniela Femia in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Jorgelina Coppa in
Google Scholar
PubMed
Search for other papers by Francesco Panzuto in
Google Scholar
PubMed
Search for other papers by Lorenzo Antonuzzo in
Google Scholar
PubMed
Search for other papers by Emilio Bajetta in
Google Scholar
PubMed
Search for other papers by Maria Pia Brizzi in
Google Scholar
PubMed
Search for other papers by Davide Campana in
Google Scholar
PubMed
Search for other papers by Laura Catena in
Google Scholar
PubMed
Search for other papers by Harry Comber in
Google Scholar
PubMed
Search for other papers by Fiona Dwane in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Dario Giuffrida in
Google Scholar
PubMed
Search for other papers by Kris Henau in
Google Scholar
PubMed
Search for other papers by Toni Ibrahim in
Google Scholar
PubMed
Search for other papers by Riccardo Marconcini in
Google Scholar
PubMed
Search for other papers by Sara Massironi in
Google Scholar
PubMed
Search for other papers by Maja Primic Žakelj in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Elizabeth Van Eycken in
Google Scholar
PubMed
Search for other papers by Jan Maaten Van der Zwan in
Google Scholar
PubMed
Search for other papers by Tina Žagar in
Google Scholar
PubMed
Search for other papers by Luca Giacomelli in
Google Scholar
PubMed
Search for other papers by Rosalba Miceli in
Google Scholar
PubMed
Search for other papers by NEPscore Working Group in
Google Scholar
PubMed
Tumor Society (ENETS) Center of Excellence for the treatment of gastroenteropancreatic (GEP)-NETs; (ii) a European external validation cohort, which comprised rare NET patients included in the database of the pilot study of the European project
Barts and the London School of Medicine, Institute of Endocrinology, Centre for Endocrinology, University of London, London EC1M 6BQ, UK
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Ilan Shimon in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
the treatment of these tumours ( Reubi et al . 1990 ). The SSAs have been used in the treatment of NETs, and specifically of gastroenteropancreatic NETs (GEP-NETs), for many years: they may help in alleviating symptoms associated with functional
Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Istituto Auxologico Italiano IRCCS, Milan, Italy
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
Search for other papers by Alessandra Dicitore in
Google Scholar
PubMed
Search for other papers by Concetta Sciammarella in
Google Scholar
PubMed
Search for other papers by Sergio Di Molfetta in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
( n = 8) 0 0 (2A) 75 13 38 IHC Unger et al. (2008) –, not evaluated; GEP, Gastroenteropancreatic; GI, gastrointestinal; IHC, immunohistochemistry; ISH, in situ hybridization; NEC, neuroendocrine carcinoma; RT
Search for other papers by Marianne E Pavel in
Google Scholar
PubMed
Search for other papers by Christine Sers in
Google Scholar
PubMed
, bevacizumab; EVE, everolimus; GEP, gastroenteropancreatic; IFN, interferon-alpha; LAN, lanreotide; NA, not available; NET, neuroendocrine tumor; NS, statistically not significant; OCT, octreotide; PAS, pasireotide; PFS, progression free survival; pNET
Search for other papers by Lena Weindl in
Google Scholar
PubMed
Search for other papers by Imke Atreya in
Google Scholar
PubMed
Institute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Search for other papers by Peter Dietrich in
Google Scholar
PubMed
Search for other papers by Sabine Neubeck in
Google Scholar
PubMed
Deutsches Zentrum Immuntherapie DZI, Erlangen, Germany
Comprehensive Cancer Center CCC-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Search for other papers by Markus F Neurath in
Google Scholar
PubMed
Deutsches Zentrum Immuntherapie DZI, Erlangen, Germany
Comprehensive Cancer Center CCC-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
. 2017 ) and appear in a wide variety of organs; however, the most common sites are the gastroenteropancreatic (GEP) system and the lung ( Dasari et al. 2017 ). While low-grade NENs represent a disparate group with well to moderate outcome profiles
Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Search for other papers by Josh Mailman in
Google Scholar
PubMed
Search for other papers by Michael W Rabow in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by Sarah Creed in
Google Scholar
PubMed
Search for other papers by Hagen F Kennecke in
Google Scholar
PubMed
Search for other papers by Janice Pasieka in
Google Scholar
PubMed
Search for other papers by Jennifer Zuar in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
Search for other papers by Lauren Fishbein in
Google Scholar
PubMed
, ease of administration, and tolerability, SSAs are generally considered as first-line therapeutic option in well-differentiated gastroenteropancreatic NETs (GEP-NETs). The role of continuing SSAs after disease progression is debatable ( Strosberg et al